MGI Tech Addresses Concerns Regarding U.S. Biosecure Act Inclusion
MGI Tech, a key player in the gene sequencing industry, clarified on Sunday that its role as an upstream equipment provider does not entail data collection. This clarification comes in response to the inclusion of its name in the proposed U.S. Biosecure Act.
In a filing to the Shanghai stock exchange, MGI Tech emphasized that the data generated by customers on their sequencing platform is entirely under the control of the customers. The company asserted that it does not participate in the collection, storage, processing, or control of the data.
GemPharmatech Clarifies Position on Human Genome Sequences Analysis
In a separate statement, GemPharmatech listed on the Shanghai stock exchange, stated that it has no involvement in the analysis of human genome sequences. The company clarified that none of its technologies or samples are subject to the restrictions outlined in the proposed bill. This statement aims to address any potential misconceptions regarding GemPharmatech’s activities in the context of the proposed legislation.
Read More Innovation – Tech Foom
